Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience

We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezom...

Descripción completa

Detalles Bibliográficos
Autores principales: Fucci, Ludovica, Gensini, Lorenzo, Coppetelli, Ugo, La Barbera, Elettra Ortu, Gentile, Martina, Fiori, Luciano, Perrone, Salvatore, Cimino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184873/
https://www.ncbi.nlm.nih.gov/pubmed/35694449
http://dx.doi.org/10.1016/j.lrr.2022.100330
Descripción
Sumario:We report our retrospective analysis on 34 relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients.

Ejemplares similares